Juan R Sanchez-Ramos

List of Publications by Year
in descending order

140	13,016	43973 48	23472 111
papers	citations	h-index	g-index

146	146	146	11485
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Unified Huntington's disease rating scale: Reliability and consistency. Movement Disorders, 1996, 11, 136-142.	2.2	1,890
2	Adult Bone Marrow Stromal Cells Differentiate into Neural Cells in Vitro. Experimental Neurology, 2000, 164, 247-256.	2.0	1,369
3	Intravenous Administration of Human Umbilical Cord Blood Reduces Behavioral Deficits After Stroke in Rats. Stroke, 2001, 32, 2682-2688.	1.0	1,153
4	Trinucleotide repeat length instability and age of onset in Huntington's disease. Nature Genetics, 1993, 4, 387-392.	9.4	1,008
5	Sleep disorders and sleep effect in Parkinson's disease. Movement Disorders, 1990, 5, 280-285.	2.2	350
6	Parkinson's disease and brain levels of organochlorine pesticides. Annals of Neurology, 1994, 36, 100-103.	2.8	318
7	Intravenous versus intrastriatal cord blood administration in a rodent model of stroke. Journal of Neuroscience Research, 2003, 73, 296-307.	1.3	295
8	Neural cells derived from adult bone marrow and umbilical cord blood. Journal of Neuroscience Research, 2002, 69, 880-893.	1.3	277
9	Intravenous Administration of Human Umbilical Cord Blood Reduces Neurological Deficit in the Rat after Traumatic Brain Injury. Cell Transplantation, 2002, 11, 275-281.	1.2	263
10	Huntington's disease in venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Movement Disorders, 1990, 5, 93-99.	2.2	216
11	Effects of Crystal Form on Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine. Crystal Growth and Design, 2010, 10, 394-405.	1.4	213
12	Expression of Neural Markers in Human Umbilical Cord Blood. Experimental Neurology, 2001, 171, 109-115.	2.0	196
13	Electromagnetic Field Treatment Protects Against and Reverses Cognitive Impairment in Alzheimer's Disease Mice. Journal of Alzheimer's Disease, 2010, 19, 191-210.	1.2	189
14	Gait abnormality in essential tremor. Movement Disorders, 2004, 9, 193-196.	2.2	188
15	Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Experimental Brain Research, 2013, 228, 481-491.	0.7	179
16	Mortality in DATATOP: A Multicenter trial in early Parkinson's disease. Annals of Neurology, 1998, 43, 318-325.	2.8	176
17	Neurologic Complications of Psychomotor Stimulant Abuse. International Review of Neurobiology, 2015, 120, 131-160.	0.9	147
18	Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neuroscience, 2009, 163, 55-72.	1.1	144

#	Article	IF	Citations
19	Autonomic Dysfunction in Men with Parkinsonâ€™s Disease. European Neurology, 1992, 32, 134-140.	0.6	134
20	Human Umbilical Cord Blood Cells Express Neural Antigens after Transplantation into the Developing Rat Brain. Cell Transplantation, 2002, 11, 265-274.	1.2	132
21	DNA damage, repair, and antioxidant systems in brain regions: a correlative study. Free Radical Biology and Medicine, 2000, 28, 779-785.	1.3	125
22	Acute neurotoxic effects of the fungal metabolite ochratoxin-A. NeuroToxicology, 2006, 27, 82-92.	1.4	123
23	Human Umbilical Cord Blood Progenitors: The Potential of These Hematopoietic Cells to Become Neural. Stem Cells, 2005, 23, 1560-1570.	1.4	117
24	Mobilized Peripheral Blood Cells Administered Intravenously Produce Functional Recovery in Stroke. Cell Transplantation, 2003, 12, 449-454.	1.2	110
25	Oxidative DNA damage in the aging mouse brain. Movement Disorders, 1999, 14, 972-980.	2.2	104
26	Improving Solubility and Pharmacokinetics of Meloxicam via Multiple-Component Crystal Formation. Molecular Pharmaceutics, 2012, 9, 2094-2102.	2.3	104
27	A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology, 2017, 88, 152-159.	1.5	104
28	GM-CSF Upregulated in Rheumatoid Arthritis Reverses Cognitive Impairment and Amyloidosis in Alzheimer Mice. Journal of Alzheimer's Disease, 2010, 21, 507-518.	1.2	101
29	Medication Development of Ibogaine as a Pharmacotherapy for Drug Dependencea. Annals of the New York Academy of Sciences, 1998, 844, 274-292.	1.8	99
30	Ropinirole for the Treatment of Early Parkinson Disease: A 12-Month Experience. Archives of Neurology, 1998, 55, 1211-1216.	4.9	96
31	Combination Therapy of Human Umbilical Cord Blood Cells and Granulocyte Colony Stimulating Factor Reduces Histopathological and Motor Impairments in an Experimental Model of Chronic Traumatic Brain Injury. PLoS ONE, 2014, 9, e90953.	1.1	94
32	Toxicity of Dieldrin for Dopaminergic Neurons in Mesencephalic Cultures. Experimental Neurology, 1998, 150, 263-271.	2.0	92
33	A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Movement Disorders, 2007, 22, 279-282.	2.2	90
34	Selective Destruction of Cultured Dopaminergic Neurons from Fetal Rat Mesencephalon by 1-Methyl-4-Phenylpyridinium: Cytochemical and Morphological Evidence. Journal of Neurochemistry, 1988, 50, 1934-1944.	2.1	89
35	Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury. Cell Transplantation, 2002, 11, 275-81.	1.2	88
36	A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease. Archives of Neurology, 2010, 67, 154.	4.9	87

#	Article	IF	Citations
37	Trauma as an etiology of parkinsonism: A historical review of the concept. Movement Disorders, 1988, 3, 30-36.	2.2	82
38	A futility study of minocycline in Huntington's disease. Movement Disorders, 2010, 25, 2219-2224.	2.2	79
39	Toxicity of 1-Methyl-4-Phenylpyridinium for Rat Dopaminergic Neurons in Culture: Selectivity and Irreversibility. Journal of Neurochemistry, 1990, 54, 1102-1109.	2.1	77
40	The independent influence of apathy and depression on cognitive functioning in Parkinson's disease.. Neuropsychology, 2010, 24, 721-730.	1.0	76
41	1-Methyl-4-phenylpyridinium (MPP+) but not 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) selectively destroys dopaminergic neurons in cultures of dissociated rat mesencephalic neurons. Neuroscience Letters, 1986, 72, 215-220.	1.0	74
42	Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease. Archives of Neurology, 2008, 65, 1582-9.	4.9	71
43	High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Movement Disorders, 1996, 11, 327-329.	2.2	70
44	Expression of brain natriuretic peptide by human bone marrow stromal cells. Experimental Neurology, 2004, 185, 191-197.	2.0	70
45	Sympathetic Skin Response and Heart Rate Variability in Patients With Huntington Disease. Archives of Neurology, 1999, 56, 1248.	4.9	55
46	Enriched chitosan nanoparticles loaded with siRNA are effective in lowering Huntington's disease gene expression following intranasal administration. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 24, 102119.	1.7	55
47	Article Commentary: The X-gal Caution in Neural Transplantation Studies. Cell Transplantation, 2000, 9, 657-667.	1.2	52
48	Can low level exposure to ochratoxin-A cause parkinsonism?. Journal of the Neurological Sciences, 2006, 249, 68-75.	0.3	51
49	Adult Hippocampal Neural Stem/Progenitor Cells In Vitro Are Vulnerable to the Mycotoxin Ochratoxin-A. Toxicological Sciences, 2007, 98, 187-197.	1.4	51
50	Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice. Experimental Neurology, 1991, 114, 73-81.	2.0	49
51	Comparison of Neuron-Like Cells Derived from Bone Marrow Stem Cells to Those Differentiated from Adult Brain Neural Stem Cells. Stem Cells and Development, 2007, 16, 747-756.	1.1	48
52	Do hematopoietic cells exposed to a neurogenic environment mimic properties of endogenous neural precursors?. Journal of Neuroscience Research, 2004, 76, 244-254.	1.3	46
53	Well-Being of Family Caregivers of Persons with Late-Stage Huntington's Disease: Lessons in Stress and Coping. Health Communication, 2009, 24, 239-248.	1.8	45
54	Chronic Cannabis Use in the Compassionate Investigational New Drug Program. Journal of Cannabis Therapeutics, 2002, 2, 3-57.	1.2	43

#	Article	IF	Citations
55	Human umbilical cord blood cells express neural antigens after transplantation into the developing rat brain. Cell Transplantation, 2002, 11, 265-74.	1.2	43
56	Four peptide hormones decrease the number of human breast adenocarcinoma cells. European Journal of Clinical Investigation, 2005, 35, 60-69.	1.7	42
57	Five cardiac hormones decrease the number of human small-cell lung cancer cells. European Journal of Clinical Investigation, 2005, 35, 388-398.	1.7	42
58	Attenuation of age-dependent oxidative damage to DNA and protein in brainstem of Tg Cu/Zn SOD mice. Neurobiology of Aging, 1998, 19, 311-316.	1.5	41
59	Chitosan-Mangafodipir nanoparticles designed for intranasal delivery of siRNA and DNA to brain. Journal of Drug Delivery Science and Technology, 2018, 43, 453-460.	1.4	41
60	Hemichorea-hemiballismus associated with acquired immune deficiency syndrome and cerebral toxoplasmosis. Movement Disorders, 1989, 4, 266-273.	2.2	39
61	A case of post-traumatic tic disorder. Movement Disorders, 1989, 4, 342-344.	2.2	39
62	Pilot Study of Granulocyte-Colony Stimulating Factor for Treatment of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 31, 843-855.	1.2	39
63	Delayed-onset dystonia associated with corticospinal tract dysfunction. Movement Disorders, 1988, 3, 201-210.	2.2	38
64	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS). JAMA Neurology, 2016, 73, 102.	4.5	38
65	Effects of environmental enrichment and physical activity on neurogenesis in transgenic PS1/APP mice. Brain Research, 2009, 1256, 173-179.	1.1	35
66	Banisterine and ParkinsonÊ¼s Disease. Clinical Neuropharmacology, 1991, 14, 391-402.	0.2	34
67	Medical marijuana in neurology. Expert Review of Neurotherapeutics, 2014, 14, 1453-1465.	1.4	34
68	Evaluation of an Î± synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease. Human Vaccines and Immunotherapeutics, 2015, 11, 922-930.	1.4	33
69	Vitamin A Metabolite, All-trans-retinoic Acid, Mediates Alternative Splicing of Protein Kinase C ÎVIII (PKCÎVIII) Isoform via Splicing Factor SC35. Journal of Biological Chemistry, 2010, 285, 25987-25995.	1.6	32
70	Four peptide hormones' specific decrease (up to 97%) of human prostate carcinoma cells. European Journal of Clinical Investigation, 2005, 35, 700-710.	1.7	31
71	Long-term cultured human umbilical cord neural-like cells transplanted into the striatum of NOD SCID mice. Brain Research Bulletin, 2007, 74, 155-163.	1.4	31
72	Differential and Better Response to Deep Brain Stimulation of Chorea Compared to Dystonia in Huntingtonâ€™s Disease. Stereotactic and Functional Neurosurgery, 2013, 91, 129-133.	0.8	31

#	Article	IF	Citations
73	Cocaine and tourette's syndrome. Annals of Neurology, 1988, 23, 423-424.	2.8	28
74	Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. Movement Disorders, 2006, 21, 1998-2001.	2.2	28
75	Effects of MDMA (â€œecstasyâ€) during adolescence on place conditioning and hippocampal neurogenesis. European Journal of Pharmacology, 2010, 628, 96-103.	1.7	26
76	Granulocyte colonyâ€stimulating factor promotes behavioral recovery in a mouse model of traumatic brain injury. Journal of Neuroscience Research, 2016, 94, 409-423.	1.3	26
77	The Parkinsonâ€™s Active Living (PAL) Program. Journal of Geriatric Psychiatry and Neurology, 2017, 30, 11-25.	1.2	26
78	Comparison of base-excision repair capacity in proliferating and differentiated PC 12 cells following acute challenge with dieldrin. Free Radical Biology and Medicine, 2001, 31, 1272-1278.	1.3	24
79	Effects of diethylmaleate on DNA damage and repair in the mouse brain. Free Radical Biology and Medicine, 2002, 33, 292-298.	1.3	24
80	Reversible parkinsonian syndrome complicating cysticercus midbrain encephalitis. Movement Disorders, 1995, 10, 215-219.	2.2	23
81	Effects of melanin and manganese on dna damage and repair in PC12-derived neurons. Free Radical Biology and Medicine, 2004, 36, 1144-1154.	1.3	23
82	Brain as the Sea of Marrow. Experimental Neurology, 2003, 184, 54-60.	2.0	21
83	Hyperkinetic movement disorders associated with HIV and other viral infections. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 100, 323-334.	1.0	21
84	Self-reported impulsivity in Huntingtonâ€™s disease patients and relationship to executive dysfunction and reward responsiveness. Journal of Clinical and Experimental Neuropsychology, 2017, 39, 694-706.	0.8	21
85	1-Methyl-4-phenylpyridinium (MPP+) increases oxidation of Cytochrome-b in rat striatal slices. Brain Research, 1988, 443, 183-189.	1.1	20
86	21-Aminosteroids Interact with the Dopamine Transporter to Protect Against 1-Methyl-4-Phenylpyridinium-Induced Neurotoxicity. Journal of Neurochemistry, 1992, 58, 328-334.	2.1	20
87	The potential of hematopoietic growth factors for treatment of Alzheimer's disease: a mini-review. BMC Neuroscience, 2008, 9, S3.	0.8	20
88	The entourage effect of the phytocannabinoids. Annals of Neurology, 2015, 77, 1083-1083.	2.8	20
89	The rise and fall of tobacco as a botanical medicine. Journal of Herbal Medicine, 2020, 22, 100374.	1.0	20
90	Granulocyte-colony stimulating factor promotes brain repair following traumatic brain injury by recruitment of microglia and increasing neurotrophic factor expression. Restorative Neurology and Neuroscience, 2016, 34, 415-431.	0.4	19

#	Article	IF	Citations
91	Levetiracetam-Induced Parkinsonism in a Huntington Disease Patient. Clinical Neuropharmacology, 2005, 28, 188-190.	0.2	18
92	Transgenic Murine Dopaminergic Neurons Expressing Human Cu/Zn Superoxide Dismutase Exhibit Increased Density in Culture, but No Resistance to Methylphenylpyridinium-Induced Degeneration. Journal of Neurochemistry, 2002, 68, 58-67.	2.1	17
93	Stem Cells from Umbilical Cord Blood. Seminars in Reproductive Medicine, 2006, 24, 358-369.	0.5	17
94	Granulocyte-colony stimulating factor (G-CSF) enhances recovery in mouse model of Parkinson's disease. Neuroscience Letters, 2011, 487, 153-157.	1.0	16
95	Preparation of Neural Progenitors from Bone Marrow and Umbilical Cord Blood. Methods in Molecular Biology, 2008, 438, 123-134.	0.4	16
96	MPP+-induced increases in extracellular potassium ion activity in rat striatal slices suggest that consequences of MPP+ neurotoxicity are spread beyond dopaminergic terminals. Brain Research, 1988, 475, 283-290.	1.1	15
97	The straight dope on addiction to dopamimetic drugs. Movement Disorders, 2002, 17, 223-225.	2.2	15
98	Green fluorescent protein bone marrow cells express hematopoietic and neural antigens in culture and migrate within the neonatal rat brain. Journal of Neuroscience Research, 2004, 76, 255-264.	1.3	15
99	Hippocampal Neurogenesis and the Brain Repair Response to Brief Stereotaxic Insertion of a Microneedle. Stem Cells International, 2013, 2013, 1-14.	1.2	15
100	Primary Malignant Tumors of the Heart: Four Cardiovascular Hormones Decrease the Number and DNA Synthesis of Human Angiosarcoma Cells. Cardiology, 2006, 105, 226-233.	0.6	14
101	In vivo administration of granulocyte colonyâ€stimulating factor restores longâ€term depression in hippocampal slices prepared from transgenic APP/PS1 mice. Journal of Neuroscience Research, 2014, 92, 975-980.	1.3	14
102	Examining Huntingtonâ€™s disease patient and informant concordance on frontally mediated behaviors. Journal of Clinical and Experimental Neuropsychology, 2015, 37, 981-987.	0.8	14
103	Selective and Nonselective Effects of 1-Methyl-4- Phenylpyridinium on Oxygen Consumption in Rat Striatal and Hippocampal Slices. Journal of Neurochemistry, 1991, 57, 1340-1346.	2.1	13
104	Psychostimulants. Neurologic Clinics, 1993, 11, 535-554.	0.8	12
105	Dieldrin elicits a widespread DNA repair and antioxidative response in mouse brain. Journal of Biochemical and Molecular Toxicology, 2007, 21, 125-135.	1.4	12
106	Hippocampal Neurogenesis. , 2016, , 821-831.		11
107	Neuroanatomical mapping of DNA repair and antioxidative responses in mouse brain: Effects of a single dose of MPTP. NeuroToxicology, 2006, 27, 1080-1093.	1.4	10
108	The role of mitochondrial DNA in Huntington's disease. Journal of Molecular Neuroscience, 1989, 1, 129-136.	1.1	9

#	Article	IF	Citations
109	Apoptosis in cultured hNT neurons. Developmental Brain Research, 2001, 127, 63-70.	2.1	9
110	Strain-Specific Differences in the Expression and Activity of Ogg1 in the CNS. Gene Expression, 2003, 11, 47-53.	0.5	8
111	Effects of an Inhibitor of Monocyte Recruitment on Recovery from Traumatic Brain Injury in Mice Treated with Granulocyte Colony-Stimulating Factor. International Journal of Molecular Sciences, 2017, 18, 1418.	1.8	8
112	Mechanisms of MPP+ Neurotoxicity: Oxyradical and Mitochondrial Inhibition Hypotheses. , 1988, , 145-152.		8
113	Transcriptional Profile of NeuroD1 Expression in a Human Fetal Astroglial Cell Line. Gene Expression, 2005, 12, 123-136.	0.5	7
114	Quantitative Analysis of Tremors in Welders. International Journal of Environmental Research and Public Health, 2011, 8, 1478-1490.	1.2	7
115	Letter to the editor. Movement Disorders, 1989, 4, 90-92.	2.2	6
116	Letters to the editor. Movement Disorders, 1989, 4, 283-285.	2.2	6
117	MPP+-induced pathophysiology demonstrates advantages of neurotoxicology studies in brain slices. Journal of Neuroscience Methods, 1989, 28, 51-57.	1.3	6
118	Levodopa-Responsive Parkinsonism in a Patient with Downâ€™s Syndrome. European Neurology, 1990, 30, 247-248.	0.6	6
119	Clinical Vignettes in Parkinson's Disease: A Collection of Unusual Medication-Induced Hallucinations, Delusions, and Compulsive Behaviours. International Journal of Neuroscience, 2011, 121, 472-476.	0.8	6
120	Cannabinoids for the Treatment of Movement Disorders. Current Treatment Options in Neurology, 2015, 17, 370.	0.7	6
121	Awareness of Chorea in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2020, 9, 99-103.	0.9	6
122	Optimizing Nanoparticle Design for Gene Therapy: Protection of Oligonucleotides from Degradation Without Impeding Release of Cargo. Nanomedicine & Nanoscience Research, 2018, 2, .	0.0	5
123	Dual-function hybrid nanoparticles with gene silencing and anti-inflammatory effects. Nanomedicine, 2022, , .	1.7	5
124	Magnetic resonance signal processing tool for diagnostic classification. , 2016, , .		4
125	Transient Microneedle Insertion into Hippocampus Triggers Neurogenesis and Decreases Amyloid Burden in a Mouse Model of Alzheimer's Disease. Cell Transplantation, 2016, 25, 1853-1861.	1.2	4
126	Recovery from Traumatic Brain Injury Following Treatment with Î”9-Tetrahydrocannabinol Is Associated with Increased Expression of Granulocyte-Colony Stimulating Factor and Other Neurotrophic Factors. Cannabis and Cannabinoid Research, 2022, 7, 415-423.	1.5	4

#	Article	IF	Citations
127	Rubratoxin B Elicits Antioxidative and DNA Repair Responses in Mouse Brain. Gene Expression, 2003, 11, 211-219.	0.5	4
128	The role of mitochondrial DNA in Huntingtonâ€™s disease. Journal of Molecular Neuroscience, 1989, 1, 129-136.	1.1	3
129	Method for Stimulation of Hippocampal Neurogenesis by Transient Microneedle Insertion. Methods in Molecular Biology, 2019, 1919, 227-235.	0.4	3
130	Data on enrichment of chitosan nanoparticles for intranasal delivery of oligonucleotides to the brain. Data in Brief, 2020, 28, 105093.	0.5	3
131	Granulocyte Colony-Stimulating Factor Enhances Brain Repair Following Traumatic Brain Injury Without Requiring Activation of Cannabinoid Receptors. Cannabis and Cannabinoid Research, 2021, 6, 48-57.	1.5	3
132	Administration of Î”⁹-Tetrahydrocannabinol Following Controlled Cortical Impact Restores Hippocampal-Dependent Working Memory and Locomotor Function. Cannabis and Cannabinoid Research, 2022, 7, 424-435.	1.5	3
133	A double-blind evaluation of ciladopa in Parkinson's disease. Movement Disorders, 1987, 2, 211-217.	2.2	2
134	Hematopoietic growth factors: Novel therapeutic strategy for Alzheimer's disease. Drugs of the Future, 2009, 34, 977.	0.0	2
135	Physiological assessment of paroxysmal dystonia secondary to subacute sclerosing panencephalitis. , 2002, 17, 154.		1
136	Relationship of Organochlorine Pesticides to Parkinsonism. , 2000, , 237-245.		1
137	An Artifact Of Liquid Emulsion Autoradiography. Biotechnic & Histochemistry, 1978, 53, 163-167.	0.4	0
138	Analysis of the Protective Effects of 21-Aminosteroids in MPP+-Induced Neurotoxicity to Dopaminergic Neurons in Mesencephalic Cultures. Annals of the New York Academy of Sciences, 1992, 648, 338-339.	1.8	0
139	Neon neurons. Neurology, 2013, 80, 1815-1815.	1.5	0
140	Toxicity of Structural Analogs of 1-methyl-4-Phenyl Pyridinium (MPP+) and Related Compounds on Dopaminergic Neurons in Culture. , 1988, , 137-143.		0